Hepatitis C Virus Infection — Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Citation(s)
A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients